Personalizing Treatment Approach in Neovascular AMD

home / case-based-roundtable-series / personalizing-treatment-approach-in-neovascular-amd

Dr. Daniel Kiernan shares insights from a recent Ophthalmology Times case-based roundtable meeting where he discusses two cases of neovascular age-related macular degeneration, reviews the clinical presentations, and assesses patient-specific factors in determining treatment choices.

Patient Case #1: 79-Year-Old Female With Neovascular Age-Related Macular Degeneration (AMD)

EP. 1: Patient Case #1: 79-Year-Old Female With Neovascular Age-Related Macular Degeneration (AMD)

Daniel F Kiernan, MD, FACS

January 11th 2023

Daniel F Kiernan, MD, FACS, provides an overview of a patient case of a 79-year-old female with neovascular AMD.

Impressions and Takeaway Points From Case #1

EP. 2: Impressions and Takeaway Points From Case #1

Daniel F Kiernan, MD, FACS

January 11th 2023

Daniel F Kiernan, MD, FACS, discusses impressions and key takeaways from a neovascular AMD patient case, focusing on treatment intervals.

Patient Case #2: 83-Year-Old Male With Neovascular AMD

EP. 3: Patient Case #2: 83-Year-Old Male With Neovascular AMD

Daniel F Kiernan, MD, FACS

January 11th 2023

Daniel F Kiernan, MD, FACS, reviews the case of an 83-year-old male patient with neovascular AMD.

Impressions and Takeaway Points From Case #2

EP. 4: Impressions and Takeaway Points From Case #2

Daniel F Kiernan, MD, FACS

January 11th 2023

Daniel F Kiernan, MD, FACS, discusses idiosyncratic biologic response to anti-VEGF treatment in a patient with neovascular AMD.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.